Loading data for QGEN — first visit, this takes a few seconds.

알림

Qiagen N.V. (QGEN)

NYSE: QGEN · 실시간 가격 · USD

43.65

+1.87 (4.48%)

종가 기준: Aug 28, 2026, 3:59 PM

43.05

-0.15%

애프터마켓: 7:56 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

4.48% (1D)

매수호가	43.25
시가총액	8.9B
매출 (ttm)	2.1B
순이익 (ttm)	409.32M
	0.62
	1.94
	22.22
	16.52
P/B (ttm)	2.65
P/S (ttm)	4.24
실적 발표일	Nov 4, 2026

매도호가	43.54
거래량	4,071,761
평균 거래량 (20일)	2,932,811
시가	42.18
전일 종가	41.78
일중 범위	42.12 - 44.21
52주 범위	32.53 - 57.82
애널리스트	n/a
목표주가	n/a
배당	$0.35 (0.8%)
배당락일	2026년 7월 7일

QGEN 소개

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, inc...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Jun 28, 1996

직원 수 5,500

상장 거래소 NYSE

티커 QGEN

웹사이트 https://www.qiagen.com

전체 기업 정보

재무 실적

2025년 Qiagen의 매출은 2.09B로, 전년 1.98B 대비 5.65% 증가했습니다. 순이익은 424.88M로, 408.28% 증가했습니다.

재무제표

어닝 서프라이즈

Qiagen가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $535.04M 예상치 하회 $0, 및 0.28% 전년 대비 성장.
EPS 0.62 예상치 상회 0.02, 및 -1.59% 전년 대비 감소.

다음 실적 발표

Qiagen N.V.의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

5일 전 · MedTech Dive

Qiagen names new CEO

Jonathan Pratt will take over the role on Sept. 1. The announcement ends Qiagen’s nearly 10-month search for a new chief executive.

5일 전 · Investing.com

Qiagen names Jonathan Pratt as CEO amid takeover talks

Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with p...

1주 전 · Zacks

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

2주 전 · Simply Wall St.

4% Undervalued? Qiagen (QGEN) As Q2 Beat And FDA Clearance Lift The Story

Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA clearance for its QIAstat Dx BCID GPF Plus AMR Pan...

2주 전 · Insider Monkey

Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0...

2 페이지 중 1